Press release
Antisense Oligonucleotide Therapeutics Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Explore our latest breakthroughs in Antisense Oligonucleotide Therapeutics Research. Learn more about our innovative pipeline today! @ Antisense Oligonucleotide Therapeutics Pipeline Outlook [https://www.delveinsight.com/sample-request/antisense-oligonucleotide-therapeutics-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Antisense Oligonucleotide Therapeutics Pipeline Report
* In June 2025, GlaxoSmithKline announced a study will assess the safety, efficacy and immune response following the sequential treatment of GlaxoSmithKline's (GSK) ASO compound (GSK3228836) and CHB-TI (GSK3528869A) in participants 18 to 65 years stable on NA treatment for CHB. The aim is to quantify the efficacy of sequential therapy as well as to determine an added value of sequential therapy over GSK3228836 therapy in CHB patients treated with NAs. In addition, the study will assess the effect of different treatment durations of GSK3228836 (12 or 24 weeks) prior to initiating GSK3528869A treatment.
* In June 2025, Laboratoires Thea conducted a study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A>G (p.Cys998X) mutation in the CEP290.
* DelveInsight's Antisense Oligonucleotide Therapeutics pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Antisense Oligonucleotide Therapeutics treatment.
* The leading Antisense Oligonucleotide Therapeutics Companies such as Ionis Pharmaceuticals, Secarna Pharmaceuticals, Aro Biotherapeutics, NeuBase Therapeutics, Bio-Path Holdings, Inc., Scopus Biopharma, Dyne Therapeutics, CAMP4 Therapeutics, Pulmotect, GeneTx Biotherapeutics, Aligos Therapeutics, WaVe Life Sciences and others.
* Promising Antisense Oligonucleotide Therapeutics Pipeline Therapies such as Bepirovirsen, QR-421a, SB012, Sepofarsen, QR-110, PGN-EDO51, GSK3228836 and others.
Stay informed about the cutting-edge advancements in Antisense Oligonucleotide Therapeutics treatments. Download for updates and be a part of the revolution in Musculoskeletal Care @ Antisense Oligonucleotide Therapeutics Clinical Trials Assessment [https://www.delveinsight.com/sample-request/antisense-oligonucleotide-therapeutics-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Antisense Oligonucleotide Therapeutics Emerging Drugs Profile
* Cobitolimod: InDex Pharmaceuticals
Cobitolimod is part of InDex Pharmaceuticals' DNA-based ImmunoModulatory Sequence (DIMS) platform. It is administered locally in the large intestine, where the substance binds to Toll-like receptor 9 (TLR9) present inside immune cells as well as on the surface of epithelial cells. The binding triggers the cells to product anti-inflammatory cytokines, agents that play an important role in reducing the inflammation and healing the wounds in the large intestine caused by UC. It is currently being evaluated in Phase III stage of development of Ulcerative colitis.
* Prexigebersen: Bio-Path Holdings
Prexigebersen (previously BP 100-1-01) is a neutral-charge, liposomal-delivered antisense cancer drug. It is designed to inhibit protein synthesis of Grb2 (growth factor receptor bound protein 2). Bio-Path is currently evaluating prexigebersen in Phase II program for the treatment of acute myeloid leukemia (AML). Prexigebersen has received orphan drug designation from the FDA and from the European Medicines Agency for AML.
The Antisense Oligonucleotide Therapeutics Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Antisense Oligonucleotide Therapeutics with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Antisense Oligonucleotide Therapeutics Treatment.
* Antisense Oligonucleotide Therapeutics Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Antisense Oligonucleotide Therapeutics Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Antisense Oligonucleotide Therapeutics market.
Learn more about Antisense Oligonucleotide Therapeutics Drugs opportunities in our groundbreaking Antisense Oligonucleotide Therapeutics research and development projects @ Antisense Oligonucleotide Therapeutics Unmet Needs [https://www.delveinsight.com/sample-request/antisense-oligonucleotide-therapeutics-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Antisense Oligonucleotide Therapeutics Companies
Ionis Pharmaceuticals, Secarna Pharmaceuticals, Aro Biotherapeutics, NeuBase Therapeutics, Bio-Path Holdings, Inc., Scopus Biopharma, Dyne Therapeutics, CAMP4 Therapeutics, Pulmotect, GeneTx Biotherapeutics, Aligos Therapeutics, WaVe Life Sciences and others.
Antisense Oligonucleotide Therapeutics pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
* Molecule Type
Antisense Oligonucleotide Therapeutics Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
Discover the latest advancements in Antisense Oligonucleotide Therapeutics treatment by visiting our website. Stay informed about how we're transforming the future of Musculoskeletal @ Antisense Oligonucleotide Therapeutics Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/antisense-oligonucleotide-therapeutics-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Antisense Oligonucleotide Therapeutics Pipeline Report
* Coverage- Global
* Antisense Oligonucleotide Therapeutics Companies- Ionis Pharmaceuticals, Secarna Pharmaceuticals, Aro Biotherapeutics, NeuBase Therapeutics, Bio-Path Holdings, Inc., Scopus Biopharma, Dyne Therapeutics, CAMP4 Therapeutics, Pulmotect, GeneTx Biotherapeutics, Aligos Therapeutics, WaVe Life Sciences and others.
* Antisense Oligonucleotide Therapeutics Pipeline Therapies- Bepirovirsen, QR-421a, SB012, Sepofarsen, QR-110, PGN-EDO51, GSK3228836 and others.
* Antisense Oligonucleotide Therapeutics Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Antisense Oligonucleotide Therapeutics Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Antisense Oligonucleotide Therapeutics Pipeline on our website @ Antisense Oligonucleotide Therapeutics Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/antisense-oligonucleotide-therapeutics-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Antisense Oligonucleotide Therapeutics: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* Cobitolimod: InDex Pharmaceuticals
* Mid Stage Products (Phase II)
* Prexigebersen: Bio-Path Holdings
* Early stage products (Phase I/II)
* ALG-020572: Aligos Therapeutics
* Inactive Products
* Antisense Oligonucleotide Therapeutics Key Companies
* Antisense Oligonucleotide Therapeutics Key Products
* Antisense Oligonucleotide Therapeutics- Unmet Needs
* Antisense Oligonucleotide Therapeutics- Market Drivers and Barriers
* Antisense Oligonucleotide Therapeutics- Future Perspectives and Conclusion
* Antisense Oligonucleotide Therapeutics Analyst Views
* Antisense Oligonucleotide Therapeutics Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=antisense-oligonucleotide-therapeutics-pipeline-appears-robust-with-15-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/antisense-oligonucleotide-therapeutics-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antisense Oligonucleotide Therapeutics Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4105402 • Views: …
More Releases from ABNewswire
InsureFortWorthTX.com Launches to Offer Affordable and Comprehensive Insurance t …
InsureFortWorthTX.com, the latest online platform from Baxter Insurance Agency, Inc., is now available to help Fort Worth residents easily compare and purchase auto, home, and life insurance from a variety of top-rated carriers.
FORT WORTH, TX - Jan 08, 2026 - Baxter Insurance Agency, Inc., a pillar of the Texas insurance landscape for over 40 years, is pleased to announce the launch of its new website, InsureFortWorthTX.com. This platform is specifically…
Dr. Zenovia Bryant-Bright Announces Upcoming Memoir: A Black Love Story of Loss, …
Image: https://www.abnewswire.com/upload/2026/01/45ff470dbcae7669354b6505319ce953.jpg
United States - Dr. Zenovia Bryant-Bright announces the release of her highly anticipated memoir, A Black Love Story of Loss, and Life After the Military , arriving January 26, 2026. This deeply personal and courageous book is more than a collection of memories, it is a testimony of survival, strength, love, and truth.
Too often, the stories of Black women who have served in the military are erased, dismissed, or…
GetInsuredTexas.com Launches as the Essential Guide to Texas Insurance Policies, …
GetInsuredTexas.com, a new website from Baxter Insurance Agency, Inc., is now live, offering a one-stop shop for Texans to navigate the complexities of the state's insurance market, from understanding policies to comparing companies.
HOUSTON, TX - Jan 11, 2026 - Baxter Insurance Agency, Inc., a trusted name in the Texas insurance industry for over 40 years, is proud to announce the launch of GetInsuredTexas.com. This new platform is designed to be…
AI and the Future of the Translation Profession - Translation Conference to Deli …
Want to work smarter with AI - not just "go with the flow"? At the conference we'll share tools, methods, and practical workflows from the field - not just theory. Upgrade your professional toolkit.
The 2026 ITA hybrid translation conference will focus on one of the most urgent needs of today's language professionals: practical, applicable knowledge for working effectively - and responsibly - with artificial intelligence in real-world translation environments.
While public…
More Releases for Therapeutic
Exosome Therapeutic Market : Detailed Overview
Introduction:
The exosome therapeutic market is a rapidly emerging segment in the field of regenerative medicine and drug delivery. Exosomes are extracellular vesicles naturally released by cells that play a crucial role in cell communication and genetic material transfer. They have gained attention for their potential applications in treating various diseases, including cancer, neurodegenerative disorders, and cardiovascular conditions. As a novel therapeutic platform, exosomes provide significant advantages such as low immunogenicity,…
Parkinson's Disease Therapeutic Market Hope for Patients: The Parkinson's Diseas …
Parkinson's Disease Therapeutic Market worth $6.51 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Parkinson's Disease Therapeutic Market - (By Drugs (Carbidopa-levodopa, Dopamine agonists, Mao-b inhibitors, COMT inhibitors, Anticholinergics, Others), By Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy), By Brand (Branded, Generics), By Route of Administration (Oral, Injectable, Intestinal Infusion, Subcutaneous, Others)),…
Global Remote Therapeutic Monitoring Market
According to a new market research report published by Global Market Estimates, the Global Remote Therapeutic Monitoring Market is projected to grow at a CAGR of 17.4% from 2023 to 2028.
Medsien, Intellihinc, Zimmer Biomet, Owlytics Healthcare, Limber Health, Medistics, RxCap, Propeller Health, HealthArc, CENSON Health, and B Castle Smith & Co., are some of the key players in the remote therapeutic monitoring market.
Browse 147 Market Data Tables and 115…
Europe Digital Therapeutic (DTx) Market
Europe Digital Therapeutic (DTx) Market report provides information about the industry, including valuable Analysis and Detailed study. This research study explores the Global Europe Digital Therapeutic (DTx) Market in detail such as industry chain structures, raw material suppliers, with manufacturing. The Europe Digital Therapeutic (DTx) market examines the primary segments of the market. This intelligent study provides historical data from forecast.It also provides the details such as whether the customers…
Recombinant Therapeutic Antibodies and Proteins Market continues to expand with …
Recombinant therapeutic protein drugs are an important class of medicines, which helps patients in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, inflammation/autoimmunity, genetic disorders, and exposure to infectious agents. The latest advancements in protein-engineering technologies have allowed drug manufacturers and developers to adjust desirable functional characteristics of proteins of interest maintaining product efficacy. Protein-based therapies…
Therapeutic Vaccine Market 2020 - 2028 Top Companies Agenus Inc., Argos Therapeu …
This detailed market study covers therapeutic vaccine market growth potentials which can assist the stake holders to understand key trends and prospects in therapeutic vaccine market identifying the growth opportunities and competitive scenarios. The report also focuses on data from different primary and secondary sources, and is analyzed using various tools. It helps to gain insights into the market's growth potential, which can help investors identify scope and opportunities. The…
